Authors
Plavinski S. L.
Doctor of Medicine, North-West State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia. E-mail: s.plavinskij@gmail.com
Shabalkin P. I.
PhD, Russian Cancer Research Center named after N.N. Blokhin, Moscow, Russia. E-mail: p.shabalkin@gmail.com
Abstract
In a last years there has been progress made in introduction of a new drugs for the treatment of uncontrolled focal epilepsy, one of which is brivaracetam. Network meta-analyses show that it has same effectiveness compared with other new drugs and, possibly, better safety profile. Cost minimization analysis show that annual cost of treatment with brivaracetam is 21 thousand rubles lower than treatment with lacosamide, 25 thousand rubles lower than with eslicarbazepine and 95 thousand rubles lower than with perampanel. Gradual replacement of principal drugs used today with brivaracetam will cut Russian Federation budget expenses from 187 million rubles (30% replacement) to 468 million rubles (75% replacement).
Key words
uncontrolled focal epilepsy, brivaracetam, lacosamide, eslicarbazepine, cost-minimization analysis, budget impact analysis
References
1. Thurman, David J., Ettore Beghi, Charles E. Begley, Anne T. Berg, Jeffrey R. Buchhalter, Ding Ding, Dale C. Hesdorffer, W. Allen Hauser, Lewis Kazis, Rosemarie Kobau, Barbara Kroner, David Labiner, Kore Liow, Giancarlo Logroscino, Marco T. Medina, Charles R. Newton, Karen Parko, Angelia Paschal, Pierre-Marie Preux, Josemir W. Sander, Anbesaw Selassie, William Theodore, Torbjörn Tomson, and Samuel Wiebe. "Standards for epidemiologic studies and surveillance of epilepsy." Epilepsia 52 (2011): 2-26. doi:10.1111/j.1528-1167.2011.03121.x.
2. Taylor, Rod S., Josemir W. Sander, Rebecca J. Taylor, and Gus A. Baker. "Predictors of health-related quality of life and costs in adults with epilepsy: A systematic review." Epilepsia 52, no. 12 (2011): 2168-180. doi:10.1111/j.1528-1167.2011.03213.x.
3. Perucca, Emilio, and Torbjörn Tomson. "The pharmacological treatment of epilepsy in adults." The Lancet Neurology 10, no. 5 (2011): 446-56. doi:10.1016/s1474-4422(11)70047-3.
4. Glauser, Tracy, Elinor Ben-Menachem, Blaise Bourgeois, Avital Cnaan, David Chadwick, Carlos Guerreiro, Reetta Kalviainen, Richard Mattson, Emilio Perucca, and Torbjorn Tomson. "ILAE Treatment Guidelines: Evidence-based Analysis of Antiepileptic Drug Efficacy and Effectiveness as Initial Monotherapy for Epileptic Seizures and Syndromes." Epilepsia 47, no. 7 (2006): 1094-120. doi:10.1111/j.1528-1167.2006.00585.x.
5. Glauser, Tracy, Elinor Ben-Menachem, Blaise Bourgeois, Avital Cnaan, Carlos Guerreiro, Reetta Kälviäinen, Richard Mattson, Jacqueline A. French, Emilio Perucca, and Torbjorn Tomson. "Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes." Epilepsia 54, no. 3 (2013): 551-63. doi:10.1111/epi.12074.
6. Fröscher, W., V. Blankenhorn, and T. W. May. Pharmakotherapie der Epilepsien: tabellarische Darstellung unter besonderer Berücksichtigung der Pharmakokinetik. Stuttgart: Schattauer, 2008.
7. Brodie, M. J., S. J. E. Barry, G. A. Bamagous, J. D. Norrie, and P. Kwan. "Patterns of treatment response in newly diagnosed epilepsy." Neurology 78, no. 20 (2012): 1548-554. doi:10.1212/wnl.0b013e3182563b19.
8. Barton, L., L. Gore, J. Hornecker, and M. Hilaire. "Eslicarbazepine and Other Treatment Advances for Focal Seizures." US Pharmacist 42, no. 1 (2017): HS21-HS24.
9. Milchakova, L. E. Epilepsy in selected subjects of the Russian Federation: epidemiology, clinic, social aspects, the possibilities of optimizing pharmacotherapy. Doctor of Medicine diss., Pirogov Russian National Research Medical University. Moscow, 2008. 1-237.
10. UCB Pharma GmbH. Dossier zur Nutzenbewertung gemaess Paragraph 35a SGB V. – UCB Pharma GmbH, 2016: 807.
11. Brigo, Francesco, Nicola Luigi Bragazzi, Raffaele Nardone, and Eugen Trinka. "Efficacy and tolerability of brivaracetam compared to lacosamide, eslicarbazepine acetate, and perampanel as adjunctive treatments in uncontrolled focal epilepsy: Results of an indirect comparison meta-analysis of RCTs." Seizure 42 (2016): 29-37. doi:10.1016/j.seizure.2016.08.007.
12. Dianov, M. A., and S. Yu. Nikitina, eds. Rosstat. Demographic yearbook 2015. Moscow: Federal Statistics Service, 2015.
13. Ngugi, Anthony K., Christian Bottomley, Immo Kleinschmidt, Josemir W. Sander, and Charles R. Newton. "Estimation of the burden of active and life-time epilepsy: A meta-analytic approach." Epilepsia 51, no. 5 (2010): 883-90. doi:10.1111/j.1528-1167.2009.02481.x.
14. Forsgren, L., E. Beghi, A. Oun, and M. Sillanpaa. "The epidemiology of epilepsy in Europe – a systematic review." European Journal of Neurology 12, no. 4 (2005): 245-53. doi:10.1111/j.1468-1331.2004.00992.x.
15. Picot, Marie-Christine, Michel Baldy-Moulinier, Jean-Pierre Daurs, Pierre Dujols, and Arielle Crespel. "The prevalence of epilepsy and pharmacoresistant epilepsy in adults: A population-based study in a Western European country." Epilepsia 49, no. 7 (2008): 1230-238. doi:10.1111/j.1528-1167.2008.01579.x.
